HER2-mutated NSCLC in Brazil shows diverse genetic patterns and treatment gaps
A new research paper was published in Volume 16 of Oncotarget, titled “Molecular landscape of HER2-mutated non-small cell…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Precursors to bone marrow cancer can stop themselves
Why do some patients with precursors to bone marrow cancer never develop the disease? Researchers…
Timepoint at which developing B-cells become cancerous impacts leukaemia treatment
New findings show that the stage of normal cell development at which B cells transform…
Immunotherapy–targeted therapy combinations show promise in rare kidney cancer subtypes
New Meta-analysis Backs Efficacy in nccRCC A new systematic review and meta-analysis have reinforced the…
Launch of National Lung Cancer Screening Program
As the National Lung Cancer Screening Program (NLCSP) prepares to roll out in July 2025,…
Cell therapy improves overall survival of patients with colorectal cancer
Colorectal cancer (CRC) is the second most common cause of death from cancer in the…
Study demonstrates drug combination is well tolerated, safe and effective for patients with aggressive blood cancer
Using real-world data, Mass General Brigham researchers reveal how the combination of two blood cancer…
Understanding how a key protein helps aggressive blood cancer grow, paving the way for targeted therapies
Acute myeloid leukaemia (AML) is an aggressive cancer affecting the blood and bone marrow that…
Researchers uncover surprising role of ‘natural killer’ cells in resistance to cancer immunotherapy
Melanoma, one of the deadliest forms of skin cancer, affects an estimated 330,000 people worldwide…
IGF2BP1: a critical driver of cancer progression and therapeutic target
The RNA-binding protein IGF2BP1 has emerged as a key regulator of cancer hallmarks, influencing tumour…